Prelude Therapeutics Inc 2025年季度报告

Financial StatementsBalance Sheets (Unaudited) Statements of Changes in Stockholders’ Equity (Unaudited)Statements of Cash Flows (Unaudited) Notes to Unaudited Interim Financial StatementsManagement’s Discussion and Analysis of Financial Condition and Results of OperationsQuantitative and Qualitative Disclosures About Market Risk Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization Noncash lease expenseStock-based compensation Amortization of premium and discount on marketable securities, net79Changes in operating assets and liabilities:Prepaid expenses and other current assets(1,048) Net cash used in operating activitiesCash flows provided by investing activities: Purchases of marketable securities(9,463)Proceeds from maturities of marketable securities71,696Purchases of property and equipment(47)Net cash provided by investing activities62,186Cash flows used in financing activities:Proceeds from the issuance of common stock in connection with the exercise of stock Cash, cash equivalents, and restricted cash at end of period$44,313$Supplemental disclosures of non-cash activities:Property and equipment in accounts payable and accrued expenses and other current$19$Unrealized loss on marketable securities 5See accompanying notes to unaudited interim financial statements. NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS development will require significant additional research and development efforts, including extensive preclinical and clinicaltesting and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure, and extensive compliance-reporting capabilities. There can be no assurance that the Company’sresearch and development will be successfully completed, adequate protection for the Company’s technology will be obtained, anyproducts developed will obtain necessary government regulatory approval, or any approved products will be commercially viable.The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-40, Presentation of Financial Statements—Going Concern, which requires management to assess the Company’sability to continue as a going concern within one year after the date the financial statements are issued. Since its inception, theCompany has incurred operating losses and had an accumulated deficit of$615.6millionas of March 31, 2025. The Company hasno product revenue to date and devotes its efforts to research and development. The Company anticipates incurring additionallosses until such time, if ever, that it can generate significant sales of its product candidates currently in development.At March 31, 2025, the Company had cash, cash equivalents, restricted cash and marketable securities totaling $103.1million. Absent additional funding, the Company believes that its cash, cash equivalents, restricted cash and marketable securities result from the outcome of the uncertainties described above. To fund its operating expenses and capital expenditure requirements, the Company plans to seek additional funding throughpublic or private equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Companymay not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliancesor other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its The complete summary of significant accounting policies included in the Company’s financial statements for the year ended December 31, 2024 can be found in “Note 3. Summary of significant accounting policies” of the Company’s Annual Report onForm 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 10, 2025. The accompanying unaudited interim financial statements have been prepared in accordance with generally acceptedaccounting principles (“GAAP”) for interim financial information, the instructions to Form 10-Qand Article 10of Regulation S-X. They do not include all of the information and notes required by GAAP for complete financial statements. In the opinion ofmanagement, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have beenincluded. Operating results for the three months ended March 31, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. The accompanying unaudited interim financial statements should be read inconjunction with the annual audited financial statements and related notes as of a